Sponsor
1 Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type k-ras colorectal carcinoma Journal of Clinical Oncology, May 23, 2013
2 Roux-en-y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The diabetes surgery study randomized clinical trial JAMA, June 5, 2013 Evidence Based Medicine
3 Aggressive Fluid and Sodium Restriction in Acute Decompensated Heart Failure: A Randomized Clinical Trial JAMA Internal Medicine, May 21, 2013 Evidence Based Medicine
4 Quantitative analysis of multiparametric prostate mr images: differentiation between prostate cancer and normal tissue and correlation with gleason scoreāa computer-aided diagnosis development study Radiology, May 24, 2013
5 Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes Clinical Cancer Research, May 24, 2013
6 Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: A placebo-controlled, randomized study, Pain Research and Management, May 24, 2013
7 Willow bark extract STW 33-I in the long-term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain Phytomedicine, June 7, 2013
8 Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: analysis of C-peptide values before and after short-term intensive insulin therapy Journal of Diabetes Investigation, June 3, 2013 Review Article
9 Corticosteroid therapy in critically ill pediatric asthmatic patients Pediatric Critical Care, June 5, 2013
10 Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins Circulation: Cardiovascular Quality and Outcomes, June 5, 2013
Sponsor
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor